Literature DB >> 17018876

Apo-metallothionein emerging as a major player in the cellular activities of metallothionein.

David H Petering1, Jianyu Zhu, Susan Krezoski, Jeffrey Meeusen, Christy Kiekenbush, Sara Krull, Todd Specher, Munira Dughish.   

Abstract

Observations of apo-metallothionein (apo-MT) have been made under a variety of physiologic circumstances, including zinc deficiency in cell culture and in rodents, cellular induction of MT by dexamethasone with concurrent Zn deficiency, a variety of tumors under normal Zn conditions, MT induction by Zn and Bi citrate, induction of hepatic MT after tumor cell injection into nude mice, and overexpression of cardiac MT in MT transgenic mice. Experiments demonstrating both the lability of Zn and Cu bound to MT and the cellular stability of apo-MT are described to help rationalize the widespread presence of this metal-depleted species. Finally, comparative in vitro and cellular experiments examined the relative reactivity of Zn- and apo-MT with nitric oxide species, showing that apo-MT is much more reactive chemically and that in cells it may be a principal reactive species within the MT pool.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018876     DOI: 10.1177/153537020623100912

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  11 in total

1.  Selective cysteine modification of metal-free human metallothionein 1a and its isolated domain fragments: Solution structural properties revealed via ESI-MS.

Authors:  Gordon W Irvine; Melissa Santolini; Martin J Stillman
Journal:  Protein Sci       Date:  2017-03-01       Impact factor: 6.725

Review 2.  Mammalian metallothionein in toxicology, cancer, and cancer chemotherapy.

Authors:  Mohammad Namdarghanbari; William Wobig; Susan Krezoski; Niloofar M Tabatabai; David H Petering
Journal:  J Biol Inorg Chem       Date:  2011-08-07       Impact factor: 3.358

3.  TSQ (6-methoxy-8-p-toluenesulfonamido-quinoline), a common fluorescent sensor for cellular zinc, images zinc proteins.

Authors:  Jeffrey W Meeusen; Henry Tomasiewicz; Andrew Nowakowski; David H Petering
Journal:  Inorg Chem       Date:  2011-07-20       Impact factor: 5.165

4.  Toxic metal proteomics: reaction of the mammalian zinc proteome with Cd²⁺.

Authors:  Mohammad Ali Namdarghanbari; Joseph Bertling; Susan Krezoski; David H Petering
Journal:  J Inorg Biochem       Date:  2014-01-25       Impact factor: 4.155

5.  Reaction of the zinc sensor FluoZin-3 with Zn(7)-metallothionein: Inquiry into the existence of a proposed weak binding site.

Authors:  Mohammad Ali Namdarghanbari; Jeffrey Meeusen; Gary Bachowski; Nicholas Giebel; Jeremiah Johnson; David H Petering
Journal:  J Inorg Biochem       Date:  2009-11-18       Impact factor: 4.155

6.  Reactivity of Zn-, Cd-, and apo-metallothionein with nitric oxide compounds: in vitro and cellular comparison.

Authors:  Jianyu Zhu; Jeffrey Meeusen; Susan Krezoski; David H Petering
Journal:  Chem Res Toxicol       Date:  2010-02-15       Impact factor: 3.739

7.  Zinc binding ligands and cellular zinc trafficking: apo-metallothionein, glutathione, TPEN, proteomic zinc, and Zn-Sp1.

Authors:  Ujala Rana; Rajendra Kothinti; Jeffrey Meeusen; Niloofar M Tabatabai; Susan Krezoski; David H Petering
Journal:  J Inorg Biochem       Date:  2007-11-28       Impact factor: 4.155

8.  Zinc trafficking 1. Probing the roles of proteome, metallothionein, and glutathione.

Authors:  Afsana Mahim; Mohammad Karim; David H Petering
Journal:  Metallomics       Date:  2021-10-20       Impact factor: 4.636

Review 9.  Proteomic High Affinity Zn2+ Trafficking: Where Does Metallothionein Fit in?

Authors:  David H Petering; Afsana Mahim
Journal:  Int J Mol Sci       Date:  2017-06-17       Impact factor: 5.923

10.  High metallothionein predicts poor survival in glioblastoma multiforme.

Authors:  Ruty Mehrian-Shai; Michal Yalon; Amos J Simon; Eran Eyal; Tatyana Pismenyuk; Itai Moshe; Shlomi Constantini; Amos Toren
Journal:  BMC Med Genomics       Date:  2015-10-22       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.